New drug shows promise for rare ovarian cancer in early trial
NCT ID NCT05348356
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tested the drug nirogacestat in 53 people with recurrent ovarian granulosa cell tumors, a rare type of ovarian cancer. The goal was to see if the drug could shrink tumors or slow the disease. Participants took nirogacestat orally, and researchers measured how many responded to treatment and how long they lived without the cancer getting worse.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- nirogacestat (a gamma secretase inhibitor oral tablet)
- What this could lead to
- If it works, this could offer a new treatment option for people with recurrent ovarian granulosa cell tumors, potentially shrinking tumors or delaying progression.
- What could go wrong
- This is a small phase 2 trial with only 53 participants, so results may not apply to everyone. The drug may not work as hoped, and side effects are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
AdventHealth Orlando
Orlando, Florida, 32804, United States
-
Columbia University Medical Center
New York, New York, 10032, United States
-
Cross Cancer Institute
Edmonton, Alberta, T6G 1Z2, Canada
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
David C. Pratt Cancer Center
St Louis, Missouri, 63141, United States
-
Froedtert and Medical College of Wisconsin
Milwaukee, Wisconsin, 53226, United States
-
Greater Baltimore Medical Center
Baltimore, Maryland, 21204, United States
-
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, 33612, United States
-
Jagiellonian Innovation Centre Clinical Research Centre
Krakow, 30-348, Poland
-
Maria Sklodowska-Curie Bialystok Oncology Center
Bialystok, 15-027, Poland
-
Maria Sklodowska-Curie National Institute of Oncology-National Research Institute, Clinic of Oncological Gynecology
Warsaw, 02-781, Poland
-
Memorial Sloan Kettering Cancer Institute
New York, New York, 10065, United States
-
OU Health Stephenson Cancer Center
Oklahoma City, Oklahoma, 73104, United States
-
Orlando Health Cancer Institute
Orlando, Florida, 32806, United States
-
UCLA-JCCC Dept. of OBGYN - Women's Health Clinical Research Unit
Los Angeles, California, 90095, United States
-
USC/Norris Comprehensive Cancer Center
Los Angeles, California, 90033, United States
-
UW/Fred Hutch Cancer Center
Seattle, Washington, 98109, United States
-
University Teaching Hospital Poznan, Department of Oncological Gynaecology
Poznan, 60-569, Poland
-
University of New Mexico Comprehensive Cancer Center
Albuquerque, New Mexico, 87102, United States
-
Women's Cancer Care
Covington, Louisiana, 70433, United States
-
Women's Cancer Center at Kettering
Kettering, Ohio, 45429, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- Can a new PET tracer light up hidden cancers?
- A Two-for-One surgery: could tube removal during Weight-Loss surgery slash ovarian cancer risk?
- Can AI spot ovarian cancer on CT scans before It's too late?
- Can Lab-Grown tumors unlock the secrets of ovarian cancer resistance?
- Can a smart drug home in on Hard-to-Treat cancers?